RE: What I like about those deal.
Given the seemingly "across the board" yield and purity improvements that the Cascade Process delivers, I bet we'll begin to see companies transition to this process for existing production drugs in addition to new drugs. I agree with Ruttan, the regulatory requirements are seemingly relatively minimal, especially as the Cascade process becomes more and more mainstream and accepted as safe.
All of this is very encouraging. Let's just keep throwing deal after deal on the pile, at some point the present value of these deals will be recognized by the market. The fact is, Mainstream PHARMA is validating this technology over and over by signing deals with Prometic, at some point the market will understand what the industry already knows.